Cailin Conner

DocwireNews

For patients with sickle cell disease (SCD), the administration of recombinant ADAMTS13 (rADAMTS13) up 160 IU/kg did not result in safety concerns or dose-limiting toxicities, according to a phase I, randomized, double-blind, placebo-controlled study presented at the 65th ASH Annual Meeting &amp; Exposition.The study assessed &ldquo;safety, tolerability, and PK [pharmacokinetics] of 40 IU/kg, 80 IU/kg, and 160 IU/kg rADAMTS13 in patients with SCD at baseline health.&rdquo; Five patients received placebo and 14 received a single dose of rADAMTS13. Of the patients who received rADAMTS13, four received 40 IU/kg (cohort 1), six received 80 IU/kg (cohort 2), and six received 160 IU/kg (cohort 3).The primary safety endpoints included treatment-emergent adverse events (TEAEs), serious TEAEs, and the occurrence of neutralizing antibodies against ADAMTS13. Secondary endpoints involved evaluating PK, which included parameters such as the maximum concentration (Cmax) and the area under the concentration-time curve (AUC) from zero (pre-dose) to 72 hours post-dose (AUC0&ndash;72).Two patients in the placebo cohort and eight patients who received rADAMTS13 experienced TEAEs; TEAEs considered related to rADAMTS13 were reported in four patients. There were no TEAEs related to bleeding or that led to study discontinuation or death.The investigators noted that no anti-ADAMTS13 neutralizing antibodies were identified within 28 days after the administration of rADAMTS13, and the baseline ADAMTS13 antigen exhibited a standard deviation (SD) of 0.68 &mu;g/mL, and rADAMTS13 displayed a dose-proportional escalation in the ADAMTS13 antigen level.In cohorts one, two, and three, the baseline-adjusted mean Cmax for ADAMTS13 antigen was 0.51 &mu;g/mL, 1.07 &mu;g/mL, and 2.08 &mu;g/mL, respectively, while the mean AUC0&ndash;72 was 18.21 h&mu;g/mL, 43.01 h&mu;g/mL, and 74.51 h*&mu;g/mL, respectively. The baseline ADAMTS13 activity had a SD of 1.06 IU/mL. In cohorts one, two, and three, the mean Cmax for baseline-adjusted ADAMTS13 activity was 0.94 IU/mL, 2.09 IU/mL, and 3.08 IU/mL, respectively.The investigators concluded that the results provide support for additional exploration of rADAMTS13 as a potential therapeutic choice for patients with SCD.ReferenceKanter J, Patwari P, Desai P, et al. Safety and pharmacokinetics of recombinant ADAMTS13 in patients with sickle cell disease: a phase 1 randomized, double-blind, placebo-controlled study. Abstract #149. Presented at the 65th American Society of Hematology Annual Meeting; December 9-12, 2023; San Diego, California.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Phase I Study Reports No Dose-Limiting Toxicities for Recombinant ADAMTS13 in Patients with SCD

Sickle Cell Disease

Recombinant ADAMTS13 treatment exhibited promising safety and efficacy profiles in patients with sickle cell disease enrolled in a phase I trial.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe